Buscar
Mostrando ítems 1-1 de 1
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
(MDPI, 2021)
A number of immune checkpoint inhibitors (ICIs) have been approved as first-line therapy in case of cisplatin-ineligible patients or as second-line therapy for patients with metastatic urothelial carcinoma (mUC) of the ...